Get started
Author

L. Cotton

Observed names: L.B. Cotton, LINDSEY COTTON, Lindsey B. Cotton, Lindsey Behlen Cotton, Lindsey Cotton
ORCID: 0009-0001-4736-6160
Observed ORCID: 0009-0001-4736-6160
OpenAlex ID: A5111152151
Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al. · Cancer Discovery · 91
The history of amputation surgery and prosthetics
1991 · R. Ham, L. Cotton · Springer eBooks · 40
Limb Amputation
1991 · R. Ham, L. Cotton · Springer eBooks · 16
Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening
2024 · Lindsey B. Cotton, Peter B. Bach, et al. · Journal of Clinical Medicine · 12
PDF
Physical and Chemical Compatibility of Extended-Release Triamcinolone Acetonide (TA-ER) with Common Local Anesthetics
2019 · J. Derek Jackson, Lindsey Cotton, et al. · Advances in Therapy · 9
PDF
Implementing fragmentomics into real world screening interventions to evaluate clinical utility among individuals with elevated risk for lung cancer (FIRSTLUNG) L301.
2024 · Lindsey Behlen Cotton, Chris Cisar, et al. · Journal of Clinical Oncology · 1
Abstract 1062: Clinical validation: A blood-based biomarker for early lung cancer detection based on circulating DNA fragmentomics
2024 · Peter Mazzone, Peter B. Bach, et al. · Cancer Research · 1
Screening for high frequency malignant disease (SHIELD).
2023 · HA NGUYEN, Lindsey Cotton, et al. · Journal of Clinical Oncology · 1
PDF
A phase II study of irinotecan, paclitaxel and oxaliplatin (IPO) in patients with multiply relapsed germ cell tumours (GCT)
2005 · J. Shamash, T. Powles, et al. · Journal of Clinical Oncology · 1
Ward management
1991 · R. Ham, L. Cotton · Springer eBooks · 1
Table 1 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
Supplementary Tables S5 and S6 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
Supp Figs (Fig S1-4) and Tables (Tables S1-4) from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
Data from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
Supplementary Methods from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
Figure 3 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
Figure 2 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
Figure 5 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
Figure 4 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024 · Peter J. Mazzone, Peter B. Bach, et al.
P2.04A.01 FIRSTLUNG (L301): Cluster Randomized Trial Evaluating the Clinical Utility of DELFI's Blood-Based Lung Cancer Screening Test
2024 · L. Cotton, C. Cisar, et al. · Journal of Thoracic Oncology
PDF
P4.04C.07 Improving the Efficiency of Lung Cancer Screening Through a Blood-based Lung Cancer Screening Test Prior to Low-Dose CT
2024 · L. Cotton, P. Bach, et al. · Journal of Thoracic Oncology
PDF
Improving the Efficiency of Lung Cancer Screening Through the Use of a Point-of-care, Blood-based Lung Cancer Screening Test Prior to Low-dose Ct Scan
2024 · LINDSEY COTTON, PETER BACH, et al. · CHEST Journal
Improved Lung Cancer Screening Outcomes Through Blood-Based Genomic Testing: Population and Payer Impact
2024 · L.B. Cotton, J. Ortendahl, et al. · American Journal of Respiratory and Critical Care Medicine
HSR24-171: Utilizing Diverse Enrollment to Validate the DELFI Fragmentome Test for Advancing Lung Cancer Screening
2024 · Lindsey B. Cotton, Peter B. Bach, et al. · Journal of the National Comprehensive Cancer Network
Abstract 1267: Projected impact of liquid biopsy screening strategies with high sensitivity in focused populations and high specificity in broad populations
2024 · Peter B. Bach, Niti U. Trivedi, et al. · Cancer Research
Works count: 35
Citation count: 173
H-index: 5
I10-index: 4
Year
Topic
Type